Bridge Therapeutics, Inc. is a development-stage biotech company pursuing FDA approval of a patented (U.S. Patent #8410092) drug combination, BT-205, for the treatment of chronic pain in opioid-experienced patients.
Our goal is to improve lives of patients living with chronic pain by developing new approaches to pain management that are safer, more effective, and non-addictive.
“Patients are able to transition from standard opioid therapy to a drug with no symptoms of withdrawal. The drug produces no euphoric feeling in the patient, which is the main reason for the abuse of pain killers.“
DR. GREG SULLIVAN